Spinal Muscular Atrophy Market to grow at a CAGR of 14%

0

No comments posted yet

Comments

Slide 1

Spinal Muscular Atrophy Market

Slide 2

Report Description and Highlights Analyst View Spinal muscular atrophy (SMA) is one of the most common genomic disorders which are caused due to the loss of specialized nerve cells known as motor neurons in the brainstem and spinal cord. The impairment of motor neurons leads to the weakness and atrophy of muscles used for the regular activities like crawling, sitting, walking and the head movement. In worst cases, the muscles used for breathing and swallowing also get affected. On the basis of severity of muscle weakness, the age of disease commencement, there are four types of spinal muscular atrophy namely type 1, type 2, type 3 and type 4. Type 1, 2 and 3 of spinal muscle atrophy appears in childhood while type 4 appears in adulthood. According to Renub Research forecast the global Spinal Muscular Atrophy Market to grow at a CAGR of 14% in the coming years. This high growth rate is primarily due to good reimbursement options in western countries, declining drug prices and projected launch of new drugs.

Slide 3

Spinal Muscular Atrophy Market One of the major growth drivers witnessing the growth of spinal muscular atrophy market is growing awareness of diagnosis and treatment of spinal muscular atrophy during the forecast period. The awareness about the spinal muscular atrophy diagnosis and treatment is growing among the patients. The recent outcome of spinal muscular atrophy treatment further plays a significant role in spreading awareness about the disease.  Additionally, increasing government and non-government support for the treatment and diagnosis of spinal muscular atrophy further boost the growth Global Spinal Muscular Atrophy Market over the coming years. The government of several countries across the world has developed regulations to help medical professionals and caregivers decide when to administer the cure to the infants with spinal muscular atrophy. For instance: In 2018, the Canadian organization of rare disorders signed a petition for funding SPINRAZA for the treatment of Canadian patients with spinal muscular atrophy. Furthermore, one of the key factors attributing to the growth of the spinal muscular atrophy market is the rising investing by the key market players for the research and development of new and effective spinal muscular atrophy therapies. Spinal muscular atrophy generally shows its symptoms in early childhood and is a prime cause of mortality in infants. According to Spinal Muscular Atrophy (SMA) Foundation 2015 statistics, spinal muscular atrophy has been affected nearly 10,000 to 25,000 children and adults in the United States. The rising incidence of damaged spinal muscular atrophy gene amongthe infants around the world is expected to boost the growth of spinal muscular atrophy in the next couple of years. On the other hand, the high cost of drugs and treatment is likely to restrain the growth of spinal muscular atrophy market over the forecast period. For example, Biogen’s Spinraza (nusinersen) medicine for spinal muscular atrophy (SMA) is estimated to cost US$ 125,000 per injection, accounting huge expense for the treatment.

Slide 4

Read more here: https://www.renub.com/global-spinal-muscular-atrophy-market-nd.php Renub Research report titled “Spinal Muscular Atrophy Market Global Forecast by Countries (United States, United Kingdom, France, Germany, Spain, Italy & Japan), Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070), Companies (Biogen Inc., Roche AG, Novartis AG, Cytokinetics Inc)” studies the global spinal muscular atrophy market and provides an all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future. Spinal Muscular Atrophy Market

Slide 5

Spinal Muscular Atrophy Market Share Analysis Global - Current & Forecast for Spinal Muscular Atrophy Patient Population Share (%), 2017 - 2026 Source: Renub Research Analysis Note: These are dummy figures; actual data given in the report

Slide 6

Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=spinal-muscular-atrophy-market-p.php Spinal Muscular Atrophy Market Market Summary Country-wise, the report provides the Spinal muscular atrophy market and market share of United States, United Kingdom, France, Germany, Spain, Italy and Japan. Number of Patients-wise the report provides the total & treated patients population and population share of United States, United Kingdom, France, Germany, Spain, Italy and Japan. Drug-wise, the report provides present and estimated global sales of Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070. Company-wise the report provides present and estimated global of Biogen Inc., Roche AG, Novartis AG and Cytokinetics Inc. Drugs Clinical Phase Study, The report provides 113 Drugs clinical study pipeline status Which is at present, globally in the various stage such as (Phase I, II and III) unknown status, recruiting, active, not recruiting, terminated or completed stage.

Slide 7

India Outbound Tourism Market Share Analysis Source: Renub Research Analysis Note: These are dummy figures; actual data given in the report Forecast for Spinal Muscular Atrophy Market by Drugs Seles 2017 - 2026

Slide 8

Key Topics Covered in Spinal Muscular Atrophy Market 1. Introduction 1.1 Market Definition 1.2 Currency Conversion 2. Research Methodology 3. Executive Summary 4. Global Spinal Muscular Atrophy Market and Patients Analysis 4.1 Spinal Muscular Atrophy Market 4.2 Spinal Muscular Atrophy Patient Numbers 4.3 Spinal Muscular Atrophy Treated Patient Number 5. Share Analysis – Global Spinal Muscular Atrophy 5.1 Country Market Share 5.2 Patients Population Share 5.3 Treated Patients Share 6. United States 6.1 Spinal Muscular Atrophy Market 6.2 Spinal Muscular Atrophy Patient Numbers 6.3 Spinal Muscular Atrophy Treated Patients

Slide 9

Key Topics Covered in Spinal Muscular Atrophy Market 7. United Kingdom 7.1 Spinal Muscular Atrophy Market 7.2 Spinal Muscular Atrophy Patient Numbers 7.3 Spinal Muscular Atrophy Treated Patient Numbers 8. Germany 8.1 Spinal Muscular Atrophy Market 8.2 Spinal Muscular Atrophy Patient Numbers 8.3 Spinal Muscular Atrophy Treated Patients 9. Italy – Spinal Muscular Atrophy 9.1 Spinal Muscular Atrophy Market 9.2 Spinal Muscular Atrophy Patient Numbers 9.3 Spinal Muscular Atrophy Treated Patient Numbers 10. France – Spinal Muscular Atrophy 10.1 Spinal Muscular Atrophy Market 10.2 Spinal Muscular Atrophy Patient Numbers 10.3 Spinal Muscular Atrophy Treated Patient Numbers 11. Spain 11.1 Spinal Muscular Atrophy Market 11.2 Spinal Muscular Atrophy Patient Numbers 11.3 Spinal Muscular Atrophy Treated Patient Numbers

Slide 10

Key Topics Covered in Spinal Muscular Atrophy Market 12. Japan 12.1 Spinal Muscular Atrophy Market 12.2 Spinal Muscular Atrophy Patients 12.3 Spinal Muscular Atrophy Treated Patient Numbers 13. Drugs Sales – Spinal Muscular Atrophy 13.1 Spinraza 13.2 AVXS-101 13.3 CK2127107 13.4 RG7916 13.5 Olesoxime 13.6 LMI070 14. Spinal Muscular Atrophy Study Status Analysis 14.1 Spinal Muscular Atrophy Clinical Study 14.2 Spinal Muscular Atrophy Drugs Development Pipeline 15. Growth Drivers 15.1 Increasing Funding for Research & Development 15.2 Biogen Access Programs 16. Challenges 16.1 High Treatment Cost 16.2 Common Side Effects

Slide 11

Key Topics Covered in Spinal Muscular Atrophy Market 17. Biogen Inc. 17.1 Business Overview 17.2 Initiatives/Strategies 17.3 Financial Insight 18. Novartis AG 18.1 Business Overview 18.2 Initiatives/Strategies 18.3 Financial Insight 19. Roche Holding AG 19.1 Business Overview 19.2 Initiatives/Strategies 19.3 Financial Insight 20. Cytokinetics, Inc. 20.1 Business Overview 20.2 Initiatives/Strategies 20.3 Financial Insight

Slide 12

Key Topics Covered in Drugs & Pharmaceuticals Market Browse Related Report : Epilepsy Drugs Market Global Allergic Conjunctivitis Market Contact Us Tel: +1-678-302-0700 (US), +91-120-421-9822 (INDIA) Email: info@renub.com

Summary: Spinal muscular atrophy (SMA) is one of the most common genomic disorders which are caused due to the loss of specialized nerve cells known as motor neurons in the brainstem and spinal cord.

Tags: spinal muscular atrophy market to grow

URL:
More by this User
Most Viewed